MA40071A - Comprimés probiotiques bi-couche à double libération - Google Patents

Comprimés probiotiques bi-couche à double libération

Info

Publication number
MA40071A
MA40071A MA040071A MA40071A MA40071A MA 40071 A MA40071 A MA 40071A MA 040071 A MA040071 A MA 040071A MA 40071 A MA40071 A MA 40071A MA 40071 A MA40071 A MA 40071A
Authority
MA
Morocco
Prior art keywords
different
probiotic
probiotics
gastrointestinal tract
dual release
Prior art date
Application number
MA040071A
Other languages
English (en)
Inventor
Anthony Blanch
Timothy Gamble
Original Assignee
Probi Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Usa Inc filed Critical Probi Usa Inc
Publication of MA40071A publication Critical patent/MA40071A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne d'une manière générale un supplément diététique et des formulations pharmaceutiques comprenant des formulations à usage oral de formes galéniques résistantes à l'acidité disposées en couches, comprenant des probiotiques et fournies sous forme d'unités individuelles de la forme galénique, unifiée ou cohésive. Chaque couche individuelle résistante à l'acidité de la forme galénique cohésive correspond à l'une des différentes charges probiotiques et profil de libération différent permettant une administration ciblée du probiotique au niveau d'une région donnée du tractus gastro-intestinal, ou aux deux charges probiotiques différentes et profils de libération différents afin de permettre une administration ciblée de différents probiotiques au niveau de régions distinctes du tractus gastro-intestinal.
MA040071A 2014-07-01 2015-06-29 Comprimés probiotiques bi-couche à double libération MA40071A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462019717P 2014-07-01 2014-07-01

Publications (1)

Publication Number Publication Date
MA40071A true MA40071A (fr) 2016-01-07

Family

ID=55019868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040071A MA40071A (fr) 2014-07-01 2015-06-29 Comprimés probiotiques bi-couche à double libération

Country Status (17)

Country Link
US (1) US10799541B2 (fr)
EP (1) EP3164145A4 (fr)
JP (1) JP2017520577A (fr)
KR (1) KR20170021350A (fr)
CN (1) CN106535909A (fr)
AP (1) AP2016009641A0 (fr)
AU (1) AU2015284425B2 (fr)
BR (1) BR112016031000B1 (fr)
CA (1) CA2951739C (fr)
CL (1) CL2016003306A1 (fr)
MA (1) MA40071A (fr)
MX (1) MX383492B (fr)
PH (1) PH12016502463A1 (fr)
RU (1) RU2736823C2 (fr)
SG (1) SG11201610250WA (fr)
WO (1) WO2016003870A1 (fr)
ZA (1) ZA201608433B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048361B1 (fr) * 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
CN108066296B (zh) * 2016-11-11 2020-11-17 南京益恒寿生命科技有限公司 一种生物学活性组分结肠靶向组合物及其应用
EP3501503A1 (fr) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Composition pour administration solide
AU2019205296B2 (en) * 2018-01-05 2021-12-23 Nubiyota Llc Compositions comprising co-selected microbiota and methods for use thereof
EP3556226B1 (fr) * 2018-04-20 2021-01-20 Raab Vitalfood GmbH Synbiotiques complexes destinés au développement d'un microbiote saine
KR102770563B1 (ko) 2018-06-18 2025-02-21 프로비 에이비 락토바실러스 플란타룸 조성물 및 이의 용도
CA3103326A1 (fr) 2018-06-18 2019-12-26 Probi Ab Compositions probiotiques et leurs utilisations
CN113728088B (zh) 2018-09-13 2025-02-14 未知君有限责任公司 治疗胃肠障碍和炎性障碍的方法和组合物
WO2020181096A1 (fr) * 2019-03-05 2020-09-10 The Texas A&M University System Combinaisons de tannase et de formulations probiotiques et procédés d'utilisation pour améliorer le métabolisme des tanins
GB201905386D0 (en) 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
GB201908154D0 (en) 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
GB201908706D0 (en) 2019-06-18 2019-07-31 Probi Ab Lactobacillus compositions and uses thereof
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
CN117159485A (zh) * 2023-08-11 2023-12-05 江中药业股份有限公司 一种益生菌香口丸及其制备方法
WO2026017258A1 (fr) 2024-07-18 2026-01-22 Probi Ab Compositions de lacticaseibacillus et leurs utilisations

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037953A (ja) * 1983-08-11 1985-02-27 Herusu Eido:Kk カルシウムを主成分とする栄養補助食品
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
DK0931543T3 (da) 1997-12-19 2002-06-17 Merck Patent Gmbh Flerlagstabletter indeholdende probiotiske mikroorganismer såsom lactobacilli eller bifidobakterier
JP2000302694A (ja) 1999-04-16 2000-10-31 Fuyuki Mitsuyama 医食兼用物質
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
ES2270982T3 (es) * 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
EP1151673A3 (fr) 2000-05-03 2002-01-02 Societe Des Produits Nestle S.A. Confiserié avec remplissage
IL156490A0 (en) 2000-12-18 2004-01-04 Probiohealth Probiotic compounds derived from lactobacillus casei strain ke01
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EP1228769A1 (fr) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Preparation symbiotique regénératrice
US20040146564A1 (en) 2001-04-05 2004-07-29 Muriel Subirade Process for making delivery matrix and uses thereof
US6627220B2 (en) 2001-07-13 2003-09-30 Scolr, Inc. Tablets containing heat sensitive materials and method for forming thereof
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20070098784A1 (en) * 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
CN100478026C (zh) * 2001-09-28 2009-04-15 纽特休迪克斯公司 用于生物学组分的传递系统
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP1344458A1 (fr) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Système d'administration de composés probiotiques
US20030175295A1 (en) 2002-03-15 2003-09-18 Richard Ticktin Composition and method for reducing odors from metabolic processes
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
TW200404544A (en) 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20050266069A1 (en) 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
ATE514418T1 (de) * 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
US20060188563A1 (en) 2003-03-27 2006-08-24 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
US7025998B2 (en) 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
WO2005019438A1 (fr) 2003-08-21 2005-03-03 Otsuka Pharmaceutical Co., Ltd. Ferment lactique capable d'immunopotentialisation des muqueuses
GB0330009D0 (en) 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
EP1713498A4 (fr) 2004-02-09 2009-07-15 Transfert Plus Sec Composition contenant un materiau polymere et utilisations associees
US20050260181A1 (en) 2004-03-05 2005-11-24 Immunopath Profile, Inc. Compositions and methods for tissue repair
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
GB0410785D0 (en) 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
WO2005115341A2 (fr) 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticules pour administration orale
DE102004026706A1 (de) 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
US20060062742A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for reduction of human malodor
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
EP1885207B1 (fr) 2005-05-18 2011-07-06 DSM IP Assets B.V. Compositions pour applications enteriques de micro-organismes
BRPI0616429B1 (pt) 2005-09-29 2021-10-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Método para estabilização de formas de administração farmacêutica contendo microorganismos
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
ES2426258T3 (es) 2005-12-14 2013-10-22 Oxthera Intellectual Property Ab Composiciones farmacéuticas que comprenden bacterias que reducen oxalato
US20070184111A1 (en) 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
CA2673120C (fr) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
WO2008122965A2 (fr) 2007-04-04 2008-10-16 Sigmoid Pharma Limited Compositions pharmaceutiques à base de cyclosporine
WO2009020595A2 (fr) * 2007-08-03 2009-02-12 Shaklee Corporation Système de complément nutritionnel
WO2009037264A2 (fr) 2007-09-17 2009-03-26 Da Volterra Administration d'agents antimicrobiens par le colon
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20110223248A1 (en) 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
AU2009207823B2 (en) 2008-01-24 2015-02-19 Société des Produits Nestlé S.A. Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule
RU2010143460A (ru) 2008-05-01 2012-06-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для терапии восстановительных состояний кишечника
WO2009149149A1 (fr) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prévention ou traitement d'une maladie immunitaire par modification de populations microflorales
US20110104239A1 (en) * 2008-06-24 2011-05-05 Wm. Wrigley Jr. Company Probiotic chewing gum method of manufacture
US20100068268A1 (en) 2008-09-15 2010-03-18 Miloud Rahmouni Starch-based microparticles for the release of agents disposed therein
US20100151019A1 (en) * 2008-11-14 2010-06-17 Portola Pharmaceuticals, Inc. SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
DK2381799T3 (en) 2009-01-27 2018-10-22 Probiotical Spa PROBIOTIC SUPPLEMENT WITH CHOCOLATE TASTE
CA2752800C (fr) 2009-02-24 2017-12-05 Ritter Pharmaceuticals, Inc. Formulations prebiotiques et methodes d'utilisation
EP2403447B1 (fr) 2009-03-06 2019-10-16 Tamarisk Technologies Group, LLC Agents bioactifs microencapsulés pour administration orale et méthodes d'utilisation associées
US8425930B2 (en) 2009-03-13 2013-04-23 The Regents Of The University Of California Prebiotic oligosaccharides
US20100330151A1 (en) 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
WO2011009848A2 (fr) * 2009-07-20 2011-01-27 Bracco Spa Utilisation thérapeutique de probiotiques
EP2459203B1 (fr) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Bactéries lactiques et bifidobactéries destinées à traiter l'endotoxémie
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101143997B1 (ko) 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
WO2011130487A1 (fr) 2010-04-14 2011-10-20 Ganeden Biotech, Inc. Compositions à base d'une confection probiotique et compositions à base de lipides
EP2563372A4 (fr) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc Formulations prébiotiques et méthodes d'utilisation
WO2011146715A1 (fr) 2010-05-19 2011-11-24 North Carolina State University Compositions et procédés pour l'administration de peptides thérapeutiques
US20140154312A1 (en) 2010-09-17 2014-06-05 Monica Gulati Oral targetted drug delivery system
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US20140065116A1 (en) 2011-03-17 2014-03-06 Giovanni Mogna Probiotic bacteria having antioxidant activity and use thereof
WO2012154738A1 (fr) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition et procédé pour améliorer la santé intestinale
JP5916846B2 (ja) 2011-05-16 2016-05-11 オルガノバランス メディカル アーゲー 細菌性感冒に対する新規な乳酸菌及びそれを含有する組成物
CN202427429U (zh) 2012-01-09 2012-09-12 北京大北农科技集团股份有限公司 一种多层微囊制备设备
US20130295227A1 (en) 2012-05-01 2013-11-07 Robbert H. ter Haar Composition Comprising a Sensitive Ingredient
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
US10028983B2 (en) * 2013-02-22 2018-07-24 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств

Also Published As

Publication number Publication date
CA2951739A1 (fr) 2016-01-07
KR20170021350A (ko) 2017-02-27
BR112016031000B1 (pt) 2022-01-25
ZA201608433B (en) 2023-05-31
PH12016502463A1 (en) 2017-04-10
JP2017520577A (ja) 2017-07-27
US10799541B2 (en) 2020-10-13
RU2736823C2 (ru) 2020-11-20
AU2015284425B2 (en) 2021-04-01
EP3164145A1 (fr) 2017-05-10
CA2951739C (fr) 2023-09-19
CN106535909A (zh) 2017-03-22
US20170100442A1 (en) 2017-04-13
AU2015284425A1 (en) 2017-01-05
CL2016003306A1 (es) 2017-06-09
MX2016016773A (es) 2017-06-30
MX383492B (es) 2025-03-04
AP2016009641A0 (en) 2016-12-31
RU2017102952A (ru) 2018-08-01
SG11201610250WA (en) 2017-01-27
BR112016031000A2 (fr) 2017-08-22
EP3164145A4 (fr) 2018-01-17
WO2016003870A1 (fr) 2016-01-07
RU2017102952A3 (fr) 2019-02-01

Similar Documents

Publication Publication Date Title
PH12016502463A1 (en) Bi-layer dual release probiotic tablets
HK1218560A1 (zh) 组成与方法
MY166518A (en) Nanocapsules containing microemulsions
TN2017000235A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
IL261982B (en) A prophylactic and therapeutic preparation based on peroxaphthalate, especially a pharmaceutical preparation
MX2014012164A (es) Composiciones a base de probioticos y un complejo de polen de abejas/arcilla, su preparacion y sus usos en nutricion y en terapeutica.
HK1201477A1 (en) Pharmaceutical composition of omeprazole
SI3003383T1 (sl) Trdni sestavek za oralno dajanje, ki vsebuje ibandronsko kislino ali njeno farmacevtsko sprejemljivo sol, in vitamin D
IL273704A (en) Pharmaceutical bilayer tablet formulations
IL272806B1 (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
PH12016500693B1 (en) Slow-release solid oral compositions
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
MX2022013541A (es) Composiciones de acido gamma-poliglutamico y zinc.
WO2014016277A3 (fr) Préparation à base de vitamine
EP2863899B8 (fr) Formulations de préparation de comprimés à libération immédiate pour administration orale de mifepristone faiblement dosé afin de traiter l'endométriose, comprimés ainsi obtenus et leur procédé de préparation
TN2015000156A1 (en) Dispersible tablet
EP3065737A4 (fr) Forme pharmaceutique à usage oral pour prévenir les maladies vasculaires, comprimé et capsule en gélatine à titre de forme pharmaceutique
ZA201500411B (en) Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
WO2013127539A3 (fr) Formulations pharmaceutiques
PL3344281T3 (pl) Kompozycja farmaceutyczna zawierająca najmniej jeden enzym trawienny do stosowania w sztucznym żywieniu
HK1233921A1 (en) Bi-layer dual release probiotic tablets
SA515360445B1 (ar) قرص قابل للتشتيت
CN302425484S (zh) 药片